Atlas FDA

Clinical Chemistry Total Bilirubin, 6L45-20 and 6L45-40. Used for the quantitative analysis of total bilirubin in human

FDA device recall Z-1425-2012 · posted 2012-04-16 · Terminated

Recall details

Recalling firm
Abbott Laboratories Inc.
Reason for recall
Abbott Laboratories has issued a recall on the Clinical Chemistry Total Bilirubin due to an under-recovery on one clinical neonatal specimen resulting in a value less than the assay linear limit.
Action taken
Abbott Laboratories plans to release a Product Correction letter to customers instructing customers to follow the steps provided in order to revise their Total Bilirubin assay parameters. The letter explained the reason for the recall, along with the patient impact. Customers were to keep the letter as part of their laboratory records and also forward a copy to any other laboratories that they may have forwarded Total Bilirubin kits. U.S. Customers should contact Customer Service at 1-877-4ABBOTT, if they have questions.
Root cause
Material/Component Contamination
Status
Terminated
Product code
CIG
Quantity affected
11,282
Distribution
Worldwide Distribution -- USA, Guatemala, Chile, Brazil, Canada, Germany, Hong Kong, Thailand, Puerto Rico, Australia, New Zealand, Trinidad & Tobago, Bermuda, Curacao, Cayman Island, and Jamaica.
Date initiated
2009-07-09
Date posted
2012-04-16
Date terminated
2014-03-07
Location
South Pasadena, CA

Monitor recalls programmatically

Recalls and clearances share one API, with change alerts when new recalls post.

Related 510(k) clearances

RecordFirmDate
TOTAL BILIRUBIN (K022339)Abbott Laboratories2002-09-13